ALKEMAlkem Laboratories Ltd.

    Alkem Laboratories forms 51% Saudi Arabia pharma joint venture subsidiary

    • Mergers & acquisitions
    • Pharmaceuticals
    A hand holding several pills and capsules of different colours against a green background
    guvo59, via Wikimedia Commons (CC0). Illustrative image.

    Alkem Laboratories (NSE: ALKEM) has incorporated Alkem Pharma Company, Limited Liability Company in the Kingdom of Saudi Arabia as a joint venture subsidiary, it said in a filing on 08 Nov 2026. The company will hold 51% of the subsidiary, which the company describes as a strategic investment to expand its business and market reach in the Kingdom of Saudi Arabia.

    The joint venture in detail

    The subsidiary was incorporated in the Kingdom of Saudi Arabia on 08 Nov 2026, in furtherance of earlier intimations dated 12 Aug 2025 and 13 Feb 2026 on a Shareholders' Agreement for the joint venture.

    Its capital is 7,500,000 SAR divided into 75,000 shares of 100 SAR each. Alkem Laboratories will subscribe to 38,250 shares of 100 SAR each, amounting to 3,825,000 SAR, for cash, which gives it 51% of the share capital.

    The subsidiary will be involved in the manufacture, import, marketing and distribution of pharmaceutical and/or nutraceutical products within the Kingdom of Saudi Arabia. The filing says no related party or promoter group interest is involved, and that governmental approvals and a completion period are not applicable.

    How it fits the company

    Alkem Laboratories reported total income of ₹3,892.90 crore for Q1 FY27 on a consolidated basis, up 11.0% year on year. The subscription of 3,825,000 SAR is a small step against that scale, and the filing does not give the rupee equivalent.

    What the joint venture means for Alkem Laboratories' shareholders

    The company's cash commitment in the subsidiary is 3,825,000 SAR for 51% of the share capital. The filing does not say how the joint venture partner is involved or who the partner is, when commercial operations will start, whether further funding will be needed beyond the subscribed capital, or what effect the investment will have on results.

    At a glance

    ItemDetail
    SubsidiaryAlkem Pharma Company, Limited Liability Company
    Incorporated08 Nov 2026, Kingdom of Saudi Arabia
    Subsidiary capital7,500,000 SAR, 75,000 shares of 100 SAR each
    Company subscription38,250 shares, 3,825,000 SAR, cash
    Holding51%
    Stated businessManufacture, import, marketing and distribution of pharmaceutical and/or nutraceutical products

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Related posts

    All Alkem Laboratories Ltd. articles